focus -WSS

focus

author：focus 2025-08-28 08:40:30 - browse：45948

Gavel and Stethoscope due process — District courts will make the first round of decisions soon on challenges to Medicare's drug price negotiation program. APStock

WASHINGTON — Pharmaceutical companies’ efforts to scuttle President Biden’s signature health care achievement, empowering Medicare to negotiate prescription drug prices, will soon face their first big tests.

District court judges could soon weigh in on the litany of court cases that major companies filed against the government — shedding light on whether drugmakers have any hope of postponing the first parts of the negotiation process, scrapping it entirely, or sending the issue up to the Supreme Court.

It’s a major moment for the Biden administration, too, as the White House ramps up its efforts to take credit for the new changes in the 2024 election. The first round of legal decisions will play out in the thick of campaign season, attorneys told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： HHS's proposed rule does nothing to address the climate crisis

knowledge

WSS

Do more moles mean more problems? Not so, says new study

Heat waves linked to early deliveries, preterm births in new study

Scientists successfully use ultrasound imaging to map brain activity

Deliver public health messages at the right time

Warren pushes Witty on UnitedHealth's control over physicians

Deliver public health messages at the right time

Wikipedia

focus

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Health insurers say they are turning to AI to cut costs, improve care

How to save PrEP access — and even expand it

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

ChatGPT in medicine: STAT answers readers' burning questions

Crowdfunding for medical bills sidesteps core problem, author says

George Santos makes 1st court appearance after pleading not guilty to 13 counts

iTeos Therapeutics debuts first data on TIGIT

Drug repurposing or repositioning? The language matters

Stigma and the return of syphilis

focus

Welsh Carson private equity firm escapes from FTC antitrust case

Biohaven protein

First Opinion Podcast: What happens when kids become caregivers?

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

HHS's proposed rule does nothing to address the climate crisis

Insmed lung disease drug hits target in key Phase 3 trial

knowledge

leisure time

explore

focus